Aberdeen Group plc Sells 21,933 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• Aberdeen Group plc has reduced its stake in Halozyme Therapeutics by 17.0%, selling 21,933 shares during the first quarter, bringing its total holding to 106,737 shares valued at approximately $6.8 million.
• Insider selling activity includes CEO Helen Torley, who sold 20,000 shares for over $1.27 million, reducing their ownership to 733,719 shares.
• Wall Street analysts have mixed ratings on Halozyme, with four "Buy", five "Hold", and two "Sell" ratings, and the average price target set at $67.11.

Aberdeen Group plc decreased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 17.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 106,737 shares of the biopharmaceutical company's stock after selling 21,933 shares during the quarter. Aberdeen Group plc owned about 0.09% of Halozyme Therapeutics worth $6,811,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of HALO. Heck Capital Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the 4th quarter worth approximately $29,000. Bessemer Group Inc. grew its position in shares of Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 207 shares during the period. Park Place Capital Corp grew its position in shares of Halozyme Therapeutics by 20.1% during the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock worth $69,000 after buying an additional 182 shares during the period. UMB Bank n.a. grew its position in shares of Halozyme Therapeutics by 267.4% during the 1st quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company's stock worth $84,000 after buying an additional 960 shares during the period. Finally, CWM LLC grew its position in shares of Halozyme Therapeutics by 46.3% during the 1st quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company's stock worth $88,000 after buying an additional 438 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently commented on HALO. Wells Fargo & Company lifted their price target on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. The Goldman Sachs Group started coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They set a "neutral" rating and a $55.00 price objective for the company. HC Wainwright boosted their price objective on shares of Halozyme Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. Leerink Partners cut shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective for the company. in a report on Tuesday, May 13th. Finally, Morgan Stanley boosted their price objective on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the company an "overweight" rating in a report on Monday, August 18th. Four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $67.11.

Halozyme Therapeutics Stock Up 0.4%

HALO traded up $0.2710 during trading on Monday, reaching $72.0910. The company had a trading volume of 910,649 shares, compared to its average volume of 1,959,019. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. Halozyme Therapeutics, Inc. has a 12 month low of $42.01 and a 12 month high of $73.47. The business's fifty day moving average price is $58.72 and its 200 day moving average price is $58.75. The company has a market cap of $8.43 billion, a P/E ratio of 16.50, a PEG ratio of 0.41 and a beta of 1.17.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping the consensus estimate of $1.23 by $0.31. The business had revenue of $325.72 million during the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm's revenue was up 40.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $63.51, for a total value of $1,270,200.00. Following the sale, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $46,598,493.69. This trade represents a 2.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 80,000 shares of company stock worth $4,532,600 in the last 90 days. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.